Blackstone Inc (NYSE:BX) announced the final closure of its Blackstone Life Sciences VI fund (BXLS), reaching a record $6.3 billion in capital commitments.
This milestone marks the largest private fund ever dedicated to life sciences, surpassing its predecessor by nearly 40%. The fund was oversubscribed, reflecting strong investor confidence in Blackstone’s strategies, the press release stated.
“Our partnerships with global leaders have produced 34 regulatory approvals of innovative medicines and devices. This track record highlights how we work successfully with industry trailblazers to help bring their most important products to patients around the world,” Nicholas Galakatos, who serves as the Global Head of Blackstone Life Sciences, said in the release.
Since its inception in 2018, Blackstone Life Sciences has focused on investing throughout the lifecycle of companies and …
This post was originally published here
